Premium
K‐ ras mutations in nonmucinous ovarian epithelial tumors
Author(s) -
Cuatrecasas Miriam,
Erill Nadina,
Musulen Eva,
Costa Irmgard,
MatiasGuiu Xavier,
Prat Jaime
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19980315)82:6<1088::aid-cncr12>3.0.co;2-2
Subject(s) - medicine , point mutation , ovarian cancer , oncology , cancer research , mutation , polymerase chain reaction , cancer , pathology , gene , biology , genetics
BACKGROUND To assess the putative prognostic value of K‐ ras mutations in nonmucinous ovarian tumors, the authors looked for K‐ ras point mutations at codons 12 and 13 in 144 nonmucinous ovarian tumors. METHODS A series of 144 consecutive, unselected, archival, nonmucinous ovarian tumors (35 benign, 12 borderline, and 97 malignant) were studied. K‐ ras mutations at codons 12 and 13 were determined by polymerase chain reaction using the restriction fragment length polymorphism method with mismatched nested primers. Extensive clinicopathologic and follow‐up data on all patients were evaluated. RESULTS The overall prevalence of K‐ ras mutations at codons 12 and 13 was 30.5% (44/144). In benign tumors, it was 20% (7/35); in borderline tumors, 25% (3/12); and in carcinomas, 35% (34/97). The presence of K‐ ras point mutations did not correlate with survival. Among the benign tumors, K‐ ras mutations were detected in three Brenner tumors with a mucinous component. CONCLUSIONS These results indicate that K‐ ras mutations are not initial events in the pathogenesis of nonmucinous ovarian tumors and do not appear to be related to survival. Cancer 1998;82:1088‐95. © 1998 American Cancer Society.